Keeping an eye on the ocular problems in dupilumab clinical trials
- PMID: 31475340
- DOI: 10.1111/bjd.18255
Keeping an eye on the ocular problems in dupilumab clinical trials
Comment on
-
Conjunctivitis in dupilumab clinical trials.Br J Dermatol. 2019 Sep;181(3):459-473. doi: 10.1111/bjd.17869. Epub 2019 May 7. Br J Dermatol. 2019. PMID: 30851191 Free PMC article.
References
-
- Wollenberg A, Ariens L, Thurau S et al. Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab - clinical characteristics and treatment. J Allergy Clin Immunol Pract 2018; 6:1778-80.
-
- Akinlade B, Guttman-Yassky E, de Bruin-Weller M et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol 2019; 181:459-73.
-
- Thyssen JP. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased interleukin-17 levels? Br J Dermatol 2018; 178:1220.
-
- de Bruin-Weller M, Graham NMH, Pirozzi G, Shumel B. Could conjunctivitis in patients with atopic dermatitis treated with dupilumab be caused by colonization with Demodex and increased IL-17 levels? Reply from the authors. Br J Dermatol 2018; 178:1220-1.
-
- Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol 2018; 154:1208-11.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical